Evidence map›Paper›PMID 41417093›Full record

ArticleEndocrine-related cancer2026

Functional analysis of AIP variants in a cohort of neuroendocrine neoplasms.

Blanca R Carranza-Zavala, Julia M Zuarth-Vázquez, Susana M López-Zelocualtecatl, Claudia Ramírez-Rentería, Maribel Rodríguez-Torres, Ernesto Sosa-Eroza, Baldomero González-Virla, Armando Gamboa-Domínguez, Alfredo A Reza-Albarrán, Laura C Hernández-Ramírez

Abstract read
In one paragraph

Article in Endocrine-related cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Blanca R Carranza-ZavalaDepartamento de Endocrinología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Julia M Zuarth-VázquezDepartamento de Endocrinología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Susana M López-ZelocualtecatlRed de Apoyo a la Investigación, Coordinación de la Investigación Científica, Universidad Nacional Autónoma de México e Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Claudia Ramírez-RenteríaUnidad de Investigación Médica en Enfermedades Endocrinas, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Maribel Rodríguez-TorresRed de Apoyo a la Investigación, Coordinación de la Investigación Científica, Universidad Nacional Autónoma de México e Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Ernesto Sosa-ErozaDepartamento de Endocrinología, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Baldomero González-VirlaDepartamento de Endocrinología, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Armando Gamboa-DomínguezDepartamento de Patología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Alfredo A Reza-AlbarránDepartamento de Endocrinología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Laura C Hernández-RamírezRed de Apoyo a la Investigación, Coordinación de la Investigación Científica, Universidad Nacional Autónoma de México e Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.ORCID 0000-0002-6599-6406

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Loss-of-function (LOF) germline AIP variants are the main genetic cause of familial isolated pituitary adenoma and gigantism. A role for this defect in other neoplasms has been suggested, but remains unclear. We investigated the frequency, associated phenotypes, and in vitro functional effects of germline AIP variants in a cohort of Mexican patients with neuroendocrine neoplasms (NENs). Blood DNA samples from 101 adults (70.3% females) with isolated or syndromic NENs (50 with pituitary neuroendocrine tumors, PitNETs) were analyzed using a next generation sequencing panel. Targeted Sanger screening was carried out in additional family members and tumor samples. Missense and intronic variants were functionally assessed via cycloheximide chase assays or quantitative polymerase chain reaction plus sequence analysis of blood cDNA, as appropriate. Two rare likely benign defects (c.787 + 9C>T and p.T231M), two variants of uncertain significance (p.R106C and p.V291_L292del), one likely pathogenic (LP, p.C238Y), and one pathogenic (p.R304*) variant were found in six cases (5.9%). One individual was diagnosed with multiple gastric NENs and five carried PitNETs. Variant p.V291_L292del produced an unstable protein (P < 0.0001 for half-life curve, compared with wild type) and was reclassified to LP. Loss of heterozygosity in a gastric neuroendocrine tumor and nonsignificantly increased protein stability were observed for p.R106C. No deleterious effects were documented for c.787 + 9C>T. In conclusion, we determined the prevalence of AIP variants in a cohort of NENs and reclassified one VUS to LP. Our findings support the causal association of AIP LOF with PitNETs, but cannot rule out a role for AIP in other NENs.

Indexed as

Intracellular Signaling Peptides and ProteinsNeuroendocrine TumorsAdultAgedCohort StudiesFemaleGerm-Line MutationHumansMaleMiddle AgedYoung Adultaryl hydrocarbon receptor-interacting proteinIntracellular Signaling Peptides and ProteinsacromegalyAIPfamilial isolated pituitary adenomagigantismneuroendocrine tumors

Identifiers

PMID41417093
PMCPMC12910572

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.